WO2001007026A3 - Methode de traitement amelioree du diabete de type ii et de l'obesite - Google Patents

Methode de traitement amelioree du diabete de type ii et de l'obesite Download PDF

Info

Publication number
WO2001007026A3
WO2001007026A3 PCT/US2000/016325 US0016325W WO0107026A3 WO 2001007026 A3 WO2001007026 A3 WO 2001007026A3 US 0016325 W US0016325 W US 0016325W WO 0107026 A3 WO0107026 A3 WO 0107026A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
obesity
improved method
treating type
type
Prior art date
Application number
PCT/US2000/016325
Other languages
English (en)
Other versions
WO2001007026A2 (fr
Inventor
William Elmer Bloomquist
Marlene Lois Cohen
Original Assignee
Lilly Co Eli
William Elmer Bloomquist
Marlene Lois Cohen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, William Elmer Bloomquist, Marlene Lois Cohen filed Critical Lilly Co Eli
Priority to AU60500/00A priority Critical patent/AU6050000A/en
Publication of WO2001007026A2 publication Critical patent/WO2001007026A2/fr
Publication of WO2001007026A3 publication Critical patent/WO2001007026A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une méthode qui a des effets agonistes sur le récepteur bêta 3 d'un patient. Cette méthode consiste à administrer quotidiennement au patient entre environ 1,0 et environ 5,0 milligrammes par kilogramme du poids de ce patient d'un composé représenté par la formule structurelle (I) ou (VIII). On administre quotidiennement de préférence entre environ 2,0 et environ 5,0 milligrammes, voire mieux, soit entre 2,0 et environ 4,8 milligrammes, et voire encore mieux, soit entre environ 3,0 et environ 4,8 milligrammes par kilogramme du poids du patient d'un composé représenté par les formules (I) ou (VIII).
PCT/US2000/016325 1999-07-22 2000-07-12 Methode de traitement amelioree du diabete de type ii et de l'obesite WO2001007026A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU60500/00A AU6050000A (en) 1999-07-22 2000-07-12 Improved method of treating type ii diabetes and obesity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14514999P 1999-07-22 1999-07-22
US60/145,149 1999-07-22

Publications (2)

Publication Number Publication Date
WO2001007026A2 WO2001007026A2 (fr) 2001-02-01
WO2001007026A3 true WO2001007026A3 (fr) 2002-02-28

Family

ID=22511805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/016325 WO2001007026A2 (fr) 1999-07-22 2000-07-12 Methode de traitement amelioree du diabete de type ii et de l'obesite

Country Status (2)

Country Link
AU (1) AU6050000A (fr)
WO (1) WO2001007026A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007025A2 (fr) * 1999-07-22 2001-02-01 Eli Lilly And Company Traitement des anomalies cardiaques au moyen d'aryloxy-propanolamines
CA2421594A1 (fr) 2000-11-10 2002-05-16 John Arnold Werner Agonistes du recepteur beta-3 d'oxindole 3-substitue
AU2002318206A1 (en) 2001-08-14 2003-03-03 Jolie Anne Bastian 3-substituted oxindole beta-3 agonists
WO2003016307A1 (fr) 2001-08-14 2003-02-27 Eli Lilly And Company Agonistes de beta-3 adrenergiques
WO2003042160A1 (fr) 2001-11-13 2003-05-22 Theravance, Inc. Agonistes de recepteur d'aryl aniline beta-2 adrenergique
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
ATE297925T1 (de) * 2001-11-20 2005-07-15 Lilly Co Eli 3-substituierte oxindol beta 3 agonisten
DE60225174T2 (de) 2001-11-20 2009-02-12 Eli Lilly And Co., Indianapolis Beta-3 adrenergische agonisten
US7009060B2 (en) 2002-01-11 2006-03-07 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
FR2840304B1 (fr) 2002-05-29 2007-05-18 Sanofi Synthelabo Derives d'oxophenyl-cyclohexyl-propanolamine, leur preparation et leur application en therapeutique
MY143244A (en) 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
JP2008507532A (ja) 2004-07-21 2008-03-13 セラヴァンス， インコーポレーテッド ジアリールエーテルβ２アドレナリン作用性レセプターアゴニスト
WO2006031556A2 (fr) 2004-09-10 2006-03-23 Theravance. Inc. Composes d'arylaniline a substitution amidine
BR112018073227A2 (pt) * 2016-05-13 2019-02-19 The Board Of Trustees Of The Leland Stanford Junior University compostos moduladores do receptor adrenérgico e métodos de uso do mesmo
CN107266341B (zh) * 2017-06-23 2020-01-07 华东师范大学 芳氧基取代丙-2-醇胺的衍生物作为β3肾上腺素能受体拮抗剂、制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611003A1 (fr) * 1993-02-09 1994-08-17 Merck & Co. Inc. Phénylsulfonamides substitués comme B3-agonistes selectives pour le traitement du diabète et de l'obésité
EP0764640A1 (fr) * 1995-09-21 1997-03-26 Eli Lilly And Company Agonistes adrénergiques bêta-3 spécifiques
EP0827746A1 (fr) * 1996-09-05 1998-03-11 Eli Lilly And Company Analogues de carbazole étant agonistes B3-adrénergiques sélectifs
WO1999029672A1 (fr) * 1997-12-05 1999-06-17 Eli Lilly And Company AGONISTES β3-ADRENERGIQUES SPECIFIQUES
WO2001007025A2 (fr) * 1999-07-22 2001-02-01 Eli Lilly And Company Traitement des anomalies cardiaques au moyen d'aryloxy-propanolamines

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0611003A1 (fr) * 1993-02-09 1994-08-17 Merck & Co. Inc. Phénylsulfonamides substitués comme B3-agonistes selectives pour le traitement du diabète et de l'obésité
EP0764640A1 (fr) * 1995-09-21 1997-03-26 Eli Lilly And Company Agonistes adrénergiques bêta-3 spécifiques
US5786356A (en) * 1995-09-21 1998-07-28 Eli Lilly And Company Selective β3 adrenergic agonists
EP0827746A1 (fr) * 1996-09-05 1998-03-11 Eli Lilly And Company Analogues de carbazole étant agonistes B3-adrénergiques sélectifs
WO1999029672A1 (fr) * 1997-12-05 1999-06-17 Eli Lilly And Company AGONISTES β3-ADRENERGIQUES SPECIFIQUES
WO2001007025A2 (fr) * 1999-07-22 2001-02-01 Eli Lilly And Company Traitement des anomalies cardiaques au moyen d'aryloxy-propanolamines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CANDELORE, MARI RIOS ET AL: "Potent and selective human.beta.3-adrenergic receptor antagonists", J. PHARMACOL. EXP. THER. (1999), 290(2), 649-655, 1999, XP001031847 *
COHEN M L ET AL: "ARYL PROPANOLAMINES: COMPARISON OF ACTIVITY AT HUMAN BETA3 RECEPTORS, RAT BETA3 RECEPTORS AND RAT ATRIAL RECEPTORS MEDIATING TACHYCARDIA", BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 126, no. 4, 1999, pages 1018 - 1024, XP001015387, ISSN: 0007-1188 *
WEBER A E ET AL: "3-pyridyloxypropanolamine agonists of the beta3 adrenergic receptor with improved pharmacokinetic properties", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 16, 18 August 1998 (1998-08-18), pages 2111 - 2116, XP004137229, ISSN: 0960-894X *
WEBER A E ET AL: "Potent, selective benzenesulfonamide agonists of the human beta3 adrenergic receptor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 9, 1 May 1998 (1998-05-01), pages 1101 - 1106, XP004137028, ISSN: 0960-894X *

Also Published As

Publication number Publication date
AU6050000A (en) 2001-02-13
WO2001007026A2 (fr) 2001-02-01

Similar Documents

Publication Publication Date Title
WO2001007026A3 (fr) Methode de traitement amelioree du diabete de type ii et de l'obesite
AU6530600A (en) Use of neurotoxin for treating cardiac muscle disorders
AU6406996A (en) Compositions for the treatment and diagnosis of body weight disorders, including obesity
AU3920900A (en) Compounds and methods to treat cardiac failure and other disorders
AU1450900A (en) Methods of treatment of type 2 diabetes
WO1999046279A3 (fr) INHIBITEURS DE LA 17β-HYDROXYSTEROIDE DESHYDROGENASE DU TYPE 5 ET DU TYPE 3 ET METHODES D'UTILISATION ASSOCIEES
WO2001010370A3 (fr) Bandage therapeutique
ZA961927B (en) Method of treating cardiac inflammatory disease.
AU9262598A (en) Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
WO2003057837A8 (fr) Procedes d'utilisation d'anticorps anti-muc18
ITTO950104A0 (it) Catetere, particolarmente per il trattamento di aritmie cardiache.
AU4130497A (en) Materials and methods relating to the diagnosis and treatment of diabetes and obesity
ZA991220B (en) Method of treating heart failure.
WO2001010427A3 (fr) Utilisation topique d'agents anti-muscarinique
AU5739800A (en) Method for direct diagnosis and treatment of pain of muscular origin
EP1235785A4 (fr) Nouveaux composes utiles pour traiter le diabete et les pathologies associees
ZA200004854B (en) Treatment of cardiac hypertrophy.
AU1867297A (en) Gene-therapeutic nucleic acid construct, production of same and use of same in the treatment of heart disorders
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
AU7595298A (en) Azolidinediones useful for the treatment of diabetes, dyslipidemia and hy pertension
ZA974918B (en) Method of treatment of sugar plant to improve the sugar content.
AU1931895A (en) Treatment of graft-versus-host disease
WO2000000159A3 (fr) Procede de traitement de troubles dermatologiques et compositions prevues a cet effet
WO2001007025A3 (fr) Traitement des anomalies cardiaques au moyen d'aryloxy-propanolamines
AU7078298A (en) Method for the diagnosis, treatment and prophylaxis of premature ejaculation andcatheter for the diagnosis, treatment and prophylaxis of premature ejaculation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP